Biotechnology firm RadioMedix has received exclusive U.S. distribution rights for radioisotope generators produced by German firm ITG Isotope Technologies Garching.
The agreement covers the marketing and distribution of germanium-68 (Ge-68)/gallium-68 (Ga-68) generators and the iQS Ga-68 labeling module for clinical and research applications in the U.S., RadioMedix said.
In a clinical trial of Ga-68 DOTATATE, the radiotracer affected the early and accurate diagnosis of patients with neuroendocrine tumors and helped gauge their response to therapy, said Dr. Izabela Tworowska, RadioMedix's chief scientific officer, in a statement.
